Please login to the form below

Not currently logged in
Email:
Password:

immuno-oncology

This page shows the latest immuno-oncology news and features for those working in and with pharma, biotech and healthcare.

Sanofi completes acquisition of immuno-oncology specialist Synthorx

Sanofi completes acquisition of immuno-oncology specialist Synthorx

fully owns the immuno-oncology specialist. . ... additional intriguing pre-clinical assets and a powerful platform that complements our ongoing oncology and immunology research.”.

Latest news

More from news
Approximately 79 fully matching, plus 304 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Immunotherapies. The challenge now is to use predictive biomarkers for non-targeted therapies, particularly in areas like immuno-oncology where determining likely response to treatment is crucial. ... Finding and using such biomarkers is complicated,

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    its role in developing immuno-oncology blockbuster Keytruda. ... Commenting on her colleague, Susan Galbraith, head of oncology at AstraZeneca’s IMED Biotech unit (and herself one of our listed leaders last year), said: “Ruth has helped transform

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    However, the company continues to study Opdivo in trials twinned with a very wide range of novel agents, with the hope of finding a combination which can take immuno-oncology (IO)

  • Immunotherapy combination trials Q&A Immunotherapy combination trials Q&A

    By Chris Learn and Martin Lachs. The immuno-oncology (IO) field is becoming incredibly crowded and competitive. ... Chris Learn is Program Manager and Martin Lachs is VP Project Management, both at Oncology Haematology, ICON plc.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... Merck/MSD looks to have gained a dominant position in checkpoint

More from intelligence
Approximately 3 fully matching, plus 54 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest from PMHub

  • Lucid Group adds more magic to the mix with four new hires

    Betty has worked on a wide variety of medical education initiatives in various therapeutic areas including immuno-oncology, infectious diseases, transplantation and multiple sclerosis. ... Megan has experience in cardiology, vaccines, dermatology and

  • Lucid Group strengthens its scientific leadership and client service team with two new hires

    editorial. With expertise in COPD, oncology and behaviour-change patient support programmes Eva is a magical addition to the team. ... Lizzie has previously worked in Global, European, and UK roles with experience in several therapy areas including immuno

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases.

  • SWITCHED ONcology

    We are stronger together. We are Switched ON. Switched ONcology is the latest thought leadership campaign from the award-winning Havas lynx portfolio. ... The campaign provides our partners with deeper insight, smarter ideas and more meaningful

  • 18 SWITCHED ONcology: The Big Communication

    Matching unprecedented clinical advances in immuno-oncology with transformative communication. Cancer. One of the most powerful words in the English dictionary. ... This new movement towards unleashing the body’s own defences against rogue cancer cells

More from PMHub
Approximately 18 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics